Able Cerebral
Able Cerebral, LLC (ACL) is an innovative technology company with patents granted. We conquered technical challenges and physiological misconceptions of brain energy molecules (mainly glucose, the safest essential biological elements after air and water) to solve the unsolvable health problems like obesity, and Alzheimer’s.
We develop products along four main category lines:
1) Applying our controlled release technology for appetite control / weight management (ChewFull);
2) Applying our proprietary timed release technologies to prevent nocturnal hypoglycemia for diabetics who are on insulin products and some oral medications;
3) Evolving unconventional technologies to prevent the progression of mild cognitive impairment (MCI), early stage Alzheimer's disease, and achieve memory recovery for later stages of Alzheimer’s disease (AD).
4) Applying our controlled release technology to strengthening digestive system, so that to prevent IBS from fast pace and stressful environments in our daily life (IBSshield).
Able Cerebral is the pioneer in connecting the dots between nocturnal hypoglycemia with cognitive and memory deterioration. Using our timed release of brain energy molecules as the foundation for brain energy supply, we are building an internal team and partnering with other technology enterprises to conquer the unmet challenge facing AD and MCI communities.
Our flagship product BrainGlucose caplet is made with a combination of several controlled release mechanisms, which has been designed and tested for diabetes patients who are suffering from nocturnal hypoglycemia. As CDC reports, nearly three hundred thousand emergency cares due to hypoglycemia incidents annually in United States alone. Even worse, there are hundreds of millions diabetics worldwide who unaware of their nocturnal hypoglycemia, which is the silent killer of their memories.
We have filed several patent applications with the USPTO and corresponding international institutions for the current and future products in the pipeline. Recently, we have been granted US and China patent for timed release of brain energy molecules.
Breakthrough News about Our Timed Release Glucose Product:
On January 31, 2017, Temple University published a study that reveals the connection of deprivation of brain glucose and the onset of early stage of Alzheimer's disease. This is the most recent prove of our theory elucidated years ago in conferences such as AAIC Boston and AADE in Philadelphia.
There are many Alzheimer's patients have been gaining miraculous effects by taking our BrainGlucose caplets to eliminate nightmares, night sweats, and hallucinations. We have presented our out patient study results on the Alzheimer's Association International Conference (AAIC) 2017 in London.
Able Cerebral, LLC (ACL) is an innovative technology company with patents granted. We conquered technical challenges and physiological misconceptions of brain energy molecules (mainly glucose, the safest essential biological elements after air and water) to solve the unsolvable health problems like obesity, and Alzheimer’s.
We develop products along four main category lines:
1) Applying our controlled release technology for appetite control / weight management (ChewFull);
2) Applying our proprietary timed release technologies to prevent nocturnal hypoglycemia for diabetics who are on insulin products and some oral medications;
3) Evolving unconventional technologies to prevent the progression of mild cognitive impairment (MCI), early stage Alzheimer's disease, and achieve memory recovery for later stages of Alzheimer’s disease (AD).
4) Applying our controlled release technology to strengthening digestive system, so that to prevent IBS from fast pace and stressful environments in our daily life (IBSshield).
Able Cerebral is the pioneer in connecting the dots between nocturnal hypoglycemia with cognitive and memory deterioration. Using our timed release of brain energy molecules as the foundation for brain energy supply, we are building an internal team and partnering with other technology enterprises to conquer the unmet challenge facing AD and MCI communities.
Our flagship product BrainGlucose caplet is made with a combination of several controlled release mechanisms, which has been designed and tested for diabetes patients who are suffering from nocturnal hypoglycemia. As CDC reports, nearly three hundred thousand emergency cares due to hypoglycemia incidents annually in United States alone. Even worse, there are hundreds of millions diabetics worldwide who unaware of their nocturnal hypoglycemia, which is the silent killer of their memories.
We have filed several patent applications with the USPTO and corresponding international institutions for the current and future products in the pipeline. Recently, we have been granted US and China patent for timed release of brain energy molecules.
Breakthrough News about Our Timed Release Glucose Product:
On January 31, 2017, Temple University published a study that reveals the connection of deprivation of brain glucose and the onset of early stage of Alzheimer's disease. This is the most recent prove of our theory elucidated years ago in conferences such as AAIC Boston and AADE in Philadelphia.
There are many Alzheimer's patients have been gaining miraculous effects by taking our BrainGlucose caplets to eliminate nightmares, night sweats, and hallucinations. We have presented our out patient study results on the Alzheimer's Association International Conference (AAIC) 2017 in London.